Literature DB >> 202680

4-aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome.

H Lundh, O Nilsson, I Rosén.   

Abstract

A 67 year old man with the myasthenic syndrome associated with small cell bronchogenic carcinoma was treated with a new drug, 4-aminopyridine. The muscle weakness showed marked improvement and electrophysiological examinations demonstrated restoration of neuromuscular transmission.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 202680      PMCID： PMC492909          DOI： 10.1136/jnnp.40.11.1109

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  7 in total

1.  The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals.

Authors:  H Lundh; S Thesleff
Journal:  Eur J Pharmacol       Date:  1977-04-21       Impact factor: 4.432

2.  Clinical, neurophysiological and morphological findings in Eaton Lambert syndrome.

Authors:  K G Henriksson; O Nilsson; I Rosén; H H Schiller
Journal:  Acta Neurol Scand       Date:  1977-08       Impact factor: 3.209

3.  [Pharmacological approach to the study of convulsive action mechanism of amino-4 pyridine].

Authors:  M Lemeignan
Journal:  Therapie       Date:  1971 Sep-Oct       Impact factor: 2.070

4.  Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.

Authors:  D Elmqvist; E H Lambert
Journal:  Mayo Clin Proc       Date:  1968-10       Impact factor: 7.616

5.  Defects of neuromuscular transmission in syndromes other than myasthenia gravis.

Authors:  E H Lambert
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

6.  Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine.

Authors:  H Lundh; S Leander; S Thesleff
Journal:  J Neurol Sci       Date:  1977-05       Impact factor: 3.181

7.  Guanidine and germine in Eaton-Lambert syndrome.

Authors:  M Cherington
Journal:  Neurology       Date:  1976-10       Impact factor: 9.910
  7 in total
  15 in total

1.  Cholinergic modulation of memory in rats.

Authors:  V Haroutunian; E Barnes; K L Davis
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Pharmacological Attenuation of Electrical Effects in a Model of Compression Neuropathy.

Authors:  Maxwell Modrak; Leigh Sundem; Ranjan Gupta; Michael J Zuscik; John Elfar
Journal:  J Bone Joint Surg Am       Date:  2019-03-20       Impact factor: 5.284

3.  Effect of 4-aminopyridine on muscle contractility in the cat [proceedings].

Authors:  W C Bowman; I W Rodger; A O Savage
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

4.  Lack of effect of 4-aminopyridine on choreic movements.

Authors:  H Lundh; C Fehling
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

5.  Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine.

Authors:  D B Sanders; Y I Kim; J F Howard; C A Goetsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

6.  Effects of 4-aminopyridine on muscle and motor unit force in canine motor neuron disease.

Authors:  M J Pinter; R F Waldeck; T C Cope; L C Cork
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

7.  Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

Authors:  D A Ingram; G R Davis; M S Schwartz; M Traub; A C Newland; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

8.  The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres.

Authors:  H Bostock; T A Sears; R M Sherratt
Journal:  J Physiol       Date:  1981       Impact factor: 5.182

9.  Slowly inactivating potassium channels induced in Xenopus oocytes by messenger ribonucleic acid from Torpedo brain.

Authors:  C B Gundersen; R Miledi; I Parker
Journal:  J Physiol       Date:  1984-08       Impact factor: 5.182

10.  Effects of 4-aminopyridine in myasthenia gravis.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.